Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Madrigal Pharmaceuticals Inc (GB:0JXI)
LSE:0JXI
RESEARCH TOOLSreports
Holding GB:0JXI?
Track your performance easily
0JXI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$122.87 - $316.00
Previous Close$207.83
Volume95.00
Average Volume (3M)87.00
Market Cap
$4.53B
Enterprise Value$3.59B
Total Cash (Recent Filing)$1.06B
Total Debt (Recent Filing)$118.06M
Price to Earnings (P/E)―
Beta2.85
Next Earnings
Nov 06, 2024EPS Estimate
-$7.05Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-25.50
Shares Outstanding21,712,677
10 Day Avg. Volume50
30 Day Avg. Volume87
Standard Deviation0.42
R-Squared0.00
Alpha0.05
Financial Highlights & Ratios
Price to Book (P/B)5.19
Price to Sales (P/S)309.14
Price to Cash Flow (P/CF)-8.40
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue244.94
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-9.32
Forecast
1Y Price Target
$358.91Price Target Upside72.70% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering11
Madrigal Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Market PenetrationThe survey suggests Rezdiffra could be prescribed to 30% of F2/F3 NASH patients, indicating strong market penetration.
Payor CoveragePayer coverage has extended to 50%+ of commercial lives covered with a target of 80%+ by year-end.
Revenue PerformanceNet sales of $14.6M tracked favorably relative to the consensus estimate of $4.6M.
Bears Say
Competitive PressureAnticipated competitive pressure from GLP-1-based therapies impacting future Rezdiffra market penetration/share driven in part by uncertainties to payer coverage policy.
Prescription Volume ConcernsNew prescriptions exiting 2Q were significantly lower than patient-modeling estimates.
Reimbursement ChallengesThe reimbursement process is difficult, requiring proof of F2/F3 diagnosis and taking an average of three weeks from prescription to first dose.
---
Options Prices
Currently, No data available
---
Ownership Overview
29.59% Insiders
28.17% Mutual Funds
<0.01% Other Institutional Investors
27.11% Public Companies and
Individual Investors
0JXI FAQ
What was Madrigal Pharmaceuticals Inc’s price range in the past 12 months?
Madrigal Pharmaceuticals Inc lowest share price was $122.87 and its highest was $316.00 in the past 12 months.
What is Madrigal Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is Madrigal Pharmaceuticals Inc’s upcoming earnings report date?
Madrigal Pharmaceuticals Inc’s upcoming earnings report date is Nov 06, 2024 which is in 30 days.
How were Madrigal Pharmaceuticals Inc’s earnings last quarter?
Madrigal Pharmaceuticals Inc released its earnings results on Aug 07, 2024. The company reported -$7.1 earnings per share for the quarter, beating the consensus estimate of -$7.537 by $0.437.
Is Madrigal Pharmaceuticals Inc overvalued?
According to Wall Street analysts Madrigal Pharmaceuticals Inc’s price is currently Undervalued.
Does Madrigal Pharmaceuticals Inc pay dividends?
Madrigal Pharmaceuticals Inc does not currently pay dividends.
What is Madrigal Pharmaceuticals Inc’s EPS estimate?
Madrigal Pharmaceuticals Inc’s EPS estimate is -$7.05.
How many shares outstanding does Madrigal Pharmaceuticals Inc have?
Madrigal Pharmaceuticals Inc has 21,712,677 shares outstanding.
What happened to Madrigal Pharmaceuticals Inc’s price movement after its last earnings report?
Madrigal Pharmaceuticals Inc reported an EPS of -$7.1 in its last earnings report, beating expectations of -$7.537. Following the earnings report the stock price went down -13.796%.
Which hedge fund is a major shareholder of Madrigal Pharmaceuticals Inc?
Among the largest hedge funds holding Madrigal Pharmaceuticals Inc’s share is Baker Bros Advisors LP. It holds Madrigal Pharmaceuticals Inc’s shares valued at 553M.
---
Madrigal Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$358.91 (72.70% Upside)
$358.91 (72.70% Upside)
Blogger Sentiment
Bullish
GB:0JXI Sentiment 92%
Sector Average 70%
Sector Average 70%
Insider Transactions
Sold Shares
Worth $1.6M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
53.51%
12-Months-Change
Fundamentals
Return on Equity
-106.27%
Trailing 12-Months
Asset Growth
263.61%
Trailing 12-Months
Company Description
Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc. engages on the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca Taub and Edward Chiang on September 2011 and is headquartered in Fort Washington, PA.
---
0JXI Earnings Call
Q2 2024
0:00 / 0:00
---
0JXI Stock 12 Month Forecast
Average Price Target
$358.91
▲(72.70% Upside)
Technical Analysis
Madrigal Pharmaceuticals
―
Viking Therapeutics
―
Akero Therapeutics
―
Galectin Therapeutics
―
Arrowhead Pharmaceuticals
―
Best Analysts Covering 0JXI
1 Year
1 Year Success Rate
11/22 ratings generated profit
1 Year Average Return
+71.73%
assigned a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +71.73% per trade.
---